National_Coverage_Determinations_Manual / Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions

Why This Topic Matters

Coverage policy for ESAs affects claim support, medical necessity review, and documentation expectations in oncology-related anemia care. Understanding the boundaries of the NCD helps coders and compliance staff distinguish covered cancer-treatment contexts from excluded uses and related manual references.

Article Sections

1. A. General

   Introduces the therapy class and explains the policy context for its use in cancer-related care. Summarizes the general coverage concern addressed by the determination.

2. B. Nationally Covered Indications

   Describes the types of cancer-related treatment situations addressed by the coverage policy. Includes the broad clinical and treatment parameters tied to Medicare coverage.

3. C. Nationally Non-Covered Indications

   Lists categories of anemia and related clinical situations that fall outside coverage under this determination. Addresses broader exclusion themes and contraindicated use contexts.

4. D. Other

   Notes remaining coverage discretion and points to related Medicare manual references. Also identifies the review timing for the NCD.